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Abstract A principal pathway of 2-methoxyethanol (ME)
metabolism is to the toxic oxidative product, methoxyacetalde-
hyde (MALD). To assess the role of aldehyde dehydrogenase
(ALDH) in MALD metabolism, in vitro MALD oxidation was
examined with liver subcellular fractions from Japanese subjects
who carried three different ALDH2 genotypes and Aldh2
knockout mice, which were generated in this study. The activity
was distributed in mitochondrial fractions of ALDH2*1/*1 and
wild type (Aldh2+/+) mice but not ALDH2*1/*2, *2/*2 subjects
or Aldh2 homozygous mutant (Aldh23/3) mice. These data
suggest that ALDH2 is a key enzyme for MALD oxidation
and ME susceptibility may be influenced by the ALDH2
genotype. ß 2000 Federation of European Biochemical Socie-
ties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
2-Methoxyethanol (ME), or ethylene glycol monomethyl
ether, is a water-miscible solvent used extensively in the chem-
ical industry. Encephalopathy, central nervous system symp-
toms, erythropenia and granulocytopenia have been reported
in workers exposed to ME [1,2]. Moreover, human reproduc-
tive toxicity, including oligospermia, azoospermia, sperm
count reduction and ovarian luteal cell toxicity, has also
been reported [2^6].
The biotransformation of ME plays an important role in
the appearance of its toxicity [7^9]. Moss et al. [10] and Miller
et al. [7] have both reported that urinary methoxyacetic acid
(MAA) excretion was a major metabolic pathway in rat. It
has been speculated that the main pathway of ME metabolism
is the oxidation to methoxyacetaldehyde (MALD) by alcohol
dehydrogenase (ADH), and the successive oxidation of
MALD to MAA by aldehyde dehydrogenase (ALDH) [8^
11]. The ADH inhibitor pyrazole reduces the conversion of
ME to MAA and concomitantly reduced the ME testicular
toxicity in rat [7,8,10]. On the other hand, an ALDH inhib-
itor, disul¢ram, did not suppress the conversion of ME to
MAA or reduce the testicular toxicity of ME [7,8,10] although
it is not clear whether the concentration of disul¢ram was
su⁄cient to inhibit ALDH completely. MALD is also known
to have genotoxic, immunotoxic and reproductive e¡ects, at
the level of in vitro exposure [12,13]. Therefore, it has re-
mained unclear whether MALD besides MAA has a toxic
function in vivo.
ALDH comprises more than nine families in humans,
ALDH1, ALDH3 and ALDH9 are in liver cytosol, and
ALDH2, ALDH4, ALDH5 and ALDH6 are in liver mito-
chondria. ALDH7 and ALDH8 are extrahepatic [14^19]. It
has not been determined which family has a key function for
MALD metabolism. It has been reported that ALDH2 me-
tabolizes shorter chain aliphatic aldehydes like acetaldehyde
[20,21]. As MALD is a short chain aliphatic aldehyde (C3), it
is considered a candidate for oxidation by ALDH2.
The genetic polymorphism of ALDH2 has been character-
ized as ALDH2*2 in relation to the wild type, ALDH2*1.
ALDH2*2 is encoded with a lysine for glutamate substitution
at residue 487 in the mature enzyme resulting in a loss of
enzymatic activity [22,23]. In addition, the ALDH2*2 pheno-
type is dominant over ALDH2*1 [24,25]. If ALDH2 has a
major role in MALD oxidation, concentrations of ME metab-
olites, including levels of MALD, may be expected to vary in
humans in relation to the ALDH2 genotype.
To investigate whether decreases in ALDH2 activity in£u-
ence ME metabolism, liver subcellular fractions were prepared
from Japanese surgical patients who carried ALDH2*1/*1,
*1/*2 or *2/*2 alleles, and examined in vitro for MALD ox-
idation activity. This approach, however, would not be de¢n-
itive on the role of ALDH2 because activity levels of many
metabolic enzymes show high interindividual variation that is
due not only to genetic polymorphisms but also to other fac-
tors including the overall state of health of the individual.
To con¢rm the in vivo signi¢cance of ALDH2 polymor-
phism, mice lacking Aldh2 were generated with the use of
gene targeting in embryonic stem (ES) cells, and MALD ox-
idation activity was assayed in their liver subcellular fractions.
2. Materials and methods
2.1. Subjects
Tissues from one hemangiosarcoma and six carcinomas were ob-
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tained during hepatic surgery from seven patients aged 40^79 years.
The non-pathological tissues peripheral to the tumors were dissected
from the pathological tissues and stored at 380‡C until analysis. All
the subjects gave their informed consent.
2.2. Chemicals
Acetaldehyde (AALD), benzaldehyde (BALD), propionaldehyde
(PALD), decylaldehyde (DALD), methanol and pyrazole analytical
grade, purity 85^98%, were purchased from Wako, Japan. MALD
was kindly supplied by Tokyo Kasei, Japan; the purity of this prep-
aration could not be determined because of polymerization during
storage but was estimated to be less than 87%.
2.3. Genotyping of human ALDH2
Genomic DNA was extracted from a small part of the liver tissue.
The genotype of human ALDH2 was checked by PCR with a com-
mon forward primer (Kb1F; 5P-CAAATTACAGGGTCAACTGC-
TAT-3P) and ALDH2*1 speci¢c reverse primer (Kb2R; 5P-CCA-
CACTCACAGTTTTCACTTC-3P), or Kb1F and ALDH2*2 speci¢c
reverse primer (Kb3R; 5P-CCACACTCACAGTTTTCACTTT-3P).
The annealing site of each primer is shown in Fig. 1A. Because
ALDH2*2 has a base substitution at exon 12, the region around
exon 12 was selected as the PCR target. The reaction mixture was
composed of approximately 100 ng genomic DNA, 2 WM of each
primer, 0.2 mM of each dNTP, 1 mM MgCl2, 1 U of rTaq polymer-
ase (Toyobo, Japan) in 50 Wl of 1Ureaction bu¡er (Toyobo, Japan).
Ampli¢cation was performed by denaturing at 94‡C for 30 s, anneal-
ing at 56‡C for 30 s and extending at 72‡C for 30 s for 30 cycles using
the program temperature control system PC-701 (Astec, Japan). Each
primer pair yielded a single 135 bp product (Fig. 1B).
2.4. Liver subcellular fractionation
Mitochondrial, cytosolic and microsomal fractions were prepared
from human and mouse liver as described by Kishimoto et al. [26]
with a minor modi¢cation.
2.5. In vitro assay of ALDH activity toward aldehydes
Oxidation activities of ALDH toward various aldehydes were mea-
sured by the change in absorbance at 340 nm due to formation of
NADH as described by Lebsack et al. [27]. Protein concentration of
the liver fraction was determined by the Bio-Rad Protein Assay. All
aldehydes were dissolved in water except DALD, which was dissolved
in methanol. When added to the assay mixture, the ¢nal concentration
of each substrate was 50 WM, and the methanol concentration did not
exceed 1%. Pyrazole was added to the reaction mixture at a concen-
tration of 50 WM to inhibit NAD activity, and methanol was shown
not to a¡ect the enzymatic reaction at that concentration.
2.6. Generation of Aldh23/3 mice
The targeting vector was constructed as described [28]. The main-
tenance, transfection, and selection of embryonic day 14 ES cells were
performed as described [29,30]. G418 and gancyclovir resistant clones
were screened for homologous recombinants by subjecting cell lysates
to PCR with an Aldh2 speci¢c forward primer (5P-CCTTACG-
GGTGCTCGGTAGAGC-3P) and a phosphoglycerate kinase (PGK)
promoter speci¢c reverse primer (5P-TGCTAAAGCGCATGCTCCA-
GACTG-3P), the annealing sites of which are shown in Fig. 2A. The
results of PCR screening were con¢rmed by Southern blot analysis;
DNA prepared from PCR positive ES clones was digested with XbaI,
fractionated by electrophoresis, transferred to a nylon membrane (Bi-
odyen B; Paul), and then hybridized with the 0.6 kb internal probe
and 0.6 kb external probe. The expected sizes of hybridizing fragments
for wild type and recombinant alleles were 4.5 and 5.5 kb, respectively
(Fig. 2B,C). ES cells heterozygous for the targeted mutation were
microinjected into C57BL/6 blastocysts, which were then implanted
into pseudopregnant ICR females. The resulting male chimeras were
mated with female C57BL/6 mice. The germ-line transmission of in-
jected ES cells was con¢rmed by the inheritance of agouti coat color
in the F1 animals, and heterozygous o¡spring (Aldh2+/3) were inter-
crossed to produce homozygous mutant (Aldh23/3) animals (F2). All
o¡spring were tested for the presence of the mutated and/or wild type
Aldh2 alleles by PCR with a Aldh2 speci¢c forward primer (5P-CCG-
TACTGACTGTCCCATGCAGTGCT-3P) in the 5P homology region,
a PGK promoter speci¢c reverse primer (5P-GGTGGATGTGGAA-
TGTGTGCGAGGC-3P) and Aldh2 speci¢c reverse primer (5P-CCGT-
ACTGACTGTCCCATGCAGTGCT-3P), where was replaced by a
PGK-neo-poly(A) cassette in the mutant allele (Fig. 2D). F2 male
mice (33^55 weeks) were used for the following examination.
2.7. Immunoblot analysis of ALDH2 protein in liver of
Aldh2 knockout mice
To prepare recombinant mouse ALDH2 protein, complementary
DNA encoding mouse ALDH2 (mALDH2) was generated by RT-
PCR with high ¢delity DNA polymerase KOD (Toyobo), sequenced,
and subcloned into pGEX-6P-3 (Pharmacia). Glutathione S-transfer-
ase fused mALDH2 protein was produced in Escherichia coli cells,
adsorbed to glutathione-Sepharose CL4B (Pharmacia), and cleaved
by PreScission Protease (Pharmacia). The recombinant mALDH2
protein and liver mitochondrial fractions derived from knockout
mice were subjected to immunoblot analysis with anti-mALDH2 anti-
body (Fig. 2E). Anti-mALDH2 polyclonal antibody was raised
against N-terminal peptides of mALDH2, which was provided by
Iwaki Glass Co., Japan. Antiserum obtained from an immunized
rabbit was puri¢ed using Ampure PA kit (Amersham).
3. Results
3.1. Genotyping of human ALDH2
The genotyping was done with genomic DNA from the
seven Japanese surgical patients and resulted in three
ALDH2*1/*1, three ALDH2*1/*2 and one ALDH2*2/*2.
3.2. MALD oxidation activity in human liver subcellular
fractions
The ALDH activities toward MALD in mitochondrial, cy-
tosolic and microsomal fractions were determined in compar-
ison with various aldehydes. It is reported that AALD and
PALD are e⁄cient substrates of ALDH2, DALD of ALDH1,
and BALD of ALDH3.
Fig. 1. Genotyping of human ALDH2. A: The position of primers
(Kb1F, Kb2R and Kb3R) used for the genotyping of ALDH2 is in-
dicated. B: PCR analysis of ALDH2 genotype. Lanes 1 and 5 are
derived from an ALDH2*1/*1 individual. Lanes 2 and 6 are derived
from an ALDH2*1/*2 individual. Lanes 3 and 7 are derived from
an ALDH2*2/*2 individual. Lane 4 indicates molecular weight
markers.
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Mitochondrial fractions from ALDH2*1/*1 individuals
exhibited high dehydrogenase activities toward AALD,
PALD and MALD (Fig. 3A), whereas those derived from
ALDH2*1/*2 individuals had very low activities toward all
three aldehydes, about one tenth the activities of those from
ALDH2*1/*1 individuals. No ALDH activity was detected
toward all examined aldehydes in the mitochondrial fraction
from the ALDH2*2/*2 individual. This result suggests that
mitochondrial ALDH activities toward these aldehydes are
derived from ALDH2. Compared with mitochondrial frac-
tions, cytosolic fractions from ALDH2*1/*1 exhibited lower
activities toward both AALD and MALD (Fig. 3B). The cy-
tosolic fraction from ALDH2*2/*2, like the mitochondrial
fractions, exhibited no ALDH activity toward AALD and
MALD. Small amounts of ALDH2 activity may be included
in the cytosolic fraction, because human liver ALDH2 activity
is known to be distributed in both mitochondria and cytosol
[31]. Three genotypes exhibited almost the same ALDH activ-
ities toward DALD in their cytosolic fractions. On the other
hand, none of the fractions examined had ALDH activities
toward BALD. It is thus reasoned that ALDH1 is expressed
in all, and ALDH3 in none of the subjects examined. None of
the microsomal fractions examined had any ALDH activity
toward any of ¢ve aldehydes (data not shown). The patterns
of enzymatic activities toward MALD were almost same as
those toward AALD and PALD, in all three fractions, in all
subjects examined. These results suggest strongly that ALDH2
is the key enzyme in the oxidation of MALD.
3.3. Generation of Aldh23/3 mice
The mouse Aldh2 genomic locus comprises 13 exons span-
ning V26 kb [32]. The targeting construct was designed to
generate the termination signal in the PGK promoter se-
quence, which was connected with exon 3. Of the 52 G418
and gancyclovir resistant clones screened for homologous re-
combination events by PCR, four clones (7.7%) were identi-
¢ed as positive. All four of these clones were con¢rmed to
contain the mutant allele by Southern blot analysis (Fig.
2B,C). Two of these were injected into C57BL/6 blastocysts,
and chimeric males were obtained, in which a large propor-
tion of cells contained the mutant allele (as revealed by coat
color) and in which the mutant allele was transmitted to the
germ line. Heterozygous o¡spring of these chimeras appeared
normal and fertile. Mating of heterozygotes yielded wild type
(Aldh2+/+), heterozygous (Aldh2+/3) and homozygous
(Aldh23/3) o¡spring (Fig. 2D). As the o¡spring were approx-
imately in the expected sex and Mendelian ratio, no substan-
tial embryonic lethality was suspected. Both males and fe-
males were fertile and no developmental problems were
observed in the Aldh23/3 homozygotes. Therefore, ALDH2
would be not essential for mouse development. This observa-
tion is consistent with the phenotype of ALDH2*2/*2 in that
no adverse developmental or physiological problems are ap-
parent.
The expression of mALDH2 protein in liver was studied by
Western blot analysis using anti-mALDH2 polyclonal anti-
body. A single band was detected in both Aldh2+/+ and
+/3 mouse mitochondrial fractions at the same size as the
recombinant mALDH2 and no such band was present in
Aldh23/3 mitochondrial fraction (Fig. 2E). Although
mALDH1, which is localized in the cytosol, has four identical
amino acid sequences to mALDH2 at the antibody recogni-
tion site, no reaction bands were recognized in cytosolic frac-
tions derived from either strain (data not shown). These re-
sults suggest strongly that anti-mALDH2 antibody recognized
only mALDH2 and con¢rm that Aldh23/3 mice produced no
mALDH2 protein.
Fig. 2. Targeted disruption of mouse Aldh2. A: Structures of the
targeting vector (pGT-5) of the mouse Aldh2 locus, and of the mu-
tant allele resulting from homologous recombination. Filled boxes
depict exons of Aldh2. The position of a set of primers (F and R)
used for the screening of ES clones is indicated. The genomic frag-
ments (neo probe and exo probe) used as probes for Southern blot
analysis are shown as a striped box, and the expected sizes of the
XbaI fragments that hybridize with the probe are indicated. The po-
sition of two sets of primers (F1, R2 and R3) used for genotyping
of targeting mice is also indicated. Abbreviations: neo, the neomy-
cin transferase gene linked to the PGK promoter; tk, thymidine ki-
nase gene derived from herpes simplex virus linked to the PGK pro-
moter. The orientations of both neo and tk are the same as that of
Aldh2. Restriction sites: Xb, XbaI; not all restriction sites are
shown in the ¢gure. B, C: Southern blot analysis of genomic DNA
extracted from ES cells for the screening of homologous recombi-
nants. The DNA was digested with XbaI and subjected to hybrid-
ization with the neo and exo probes in B and C, respectively. The
sizes of hybridizing fragments derived from wild type (WT) and
knockout (KO) alleles are shown on the right, lane number is corre-
lated in B and C. All subjects (lanes 1^4) except four are homolo-
gous recombinants. Lane 5 indicates molecular weight markers. D,
PCR analysis of Aldh2 DNA extracted from F2 mouse tails. Both
lanes 1 and 3 indicate Aldh2+/3, lanes 2 and 4 indicate Aldh23/3
and +/+, respectively. Lane 5 indicates molecular weight markers.
E: Western blot analysis of mALDH2 expression. The targeting
mouse liver mitochondrial fractions were subjected to immunoblot
analysis with anti-mALDH2 antibody. Lanes 1^3 are Aldh2+/+, +/
3 and 3/3, respectively. Lane 4 contains protein weight markers.
Lane 5 is recombinant mALDH2 protein as a size marker. Each sig-
nal was estimated at about 58 kDa.
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Fig. 3. Comparison of substrate speci¢c activities of human liver ALDH derived from three ALDH2 genotypes. A: Mitochondrial fractions
prepared from ALDH2*1/*1, *1/*2 and *2/*2 individuals. B: Cytosolic fractions, prepared when mitochondrial fractions (A) were prepared.
Values are mean þ S.E.M. of three and two subjects for ALDH2*1/*1 and *1/*2, respectively.
Fig. 4. Comparison of substrate speci¢c activities of targeting mouse liver ALDH. A: Mitochondrial fractions prepared from Aldh2+/+, +/3
and 3/3 mice. B: Cytosolic fractions, prepared when mitochondrial fractions (A) were prepared. Values are mean þ S.E.M. of three mice.
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3.4. MALD oxidation activities in knockout mouse liver
subcellular fractions
Liver mitochondrial, cytosolic and microsomal fractions de-
rived from Aldh2+/+, +/3 and 3/3 male mice were examined
for aldehyde oxidation activities. No oxidation activity was
detected in mitochondrial fractions from Aldh23/3 mice
(Fig. 4A). On the other hand, mitochondrial fractions derived
from Aldh2+/+ mice exhibited oxidation activity toward
AALD, PALD and MALD. The mitochondrial fractions
from Aldh2+/3 showed one half the activity of those from
Aldh2+/+ mice. BALD oxidation activities were low in all
examined mitochondrial fractions of three mouse genotypes.
All cytosolic fractions had very low catalyzing activity toward
AALD and MALD, whereas BALD and DALD oxidation
activities were roughly equal among the three genotypes
(Fig. 4B). Although hALDH3 is induced only in some neo-
plastic states in human liver [33], mALDH3 was expressed in
all mouse livers examined. This result suggests that ALDH3
does not play a substantial role in MALD oxidation. None of
the microsomal fractions examined had activities with any of
the substrates examined (data not shown). The characteristics
of ALDH activity toward MALD were the same as those
toward AALD; that is, MALD dehydrogenase activity was
de¢cient in mouse mitochondria without ALDH2. Those re-
sults also provide evidence that in mouse ALDH2 is the key
enzyme in the oxidation of MALD.
4. Discussion
The mouse Aldh2 gene encodes a protein of 519 amino acid
residues which shares 95.8% identity with hALDH2 [32]. The
high expression of mALDH2 is observed in liver mitochon-
dria and mALDH2 shows high a⁄nity with short chain ali-
phatic aldehydes including AALD and PALD [34]. These
characteristics indicate that the phenotype of function of
mALDH2 corresponds highly with that of hALDH2. It is
known that hALDH2*1 exhibits its activity after taking
a tetramer [24]. In the heterozygote (ALDH2*1/*2),
ALDH2*2, a mutant subunit, reduces ALDH2 activity to
13% of the native activity, apparently because the hetero-
tetramers of ALDH2*1 and ALDH2*2 subunits do not func-
tion properly [25]. This is also the case for the homotetramer
of ALDH2*2. In the present study, the oxidation activities
toward AALD in mitochondrial fractions from ALDH2*1/
*2 individuals were dramatically reduced, almost to the level
of the ALDH2*2/*2 individual. On the other hand, no
ALDH2 enzyme is expressed from the Aldh2 knockout gene
due to the stop codon in the inserted PGK promoter gene.
Aldh23/3 mitochondrial fractions completely lacked activity.
Therefore, ALDH2 activity in homozygous knockout
(Aldh23/3) mice closely corresponds with that in human
ALDH2*2/*1 and ALDH2*2/*2 subjects, and Aldh23/3
mice appear to be a valid animal model for both ALDH2*1/
*2 and ALDH2*2/*2 individuals.
Aldehydes such as formaldehyde and AALD are toxic in
the human body. Their toxicity is in£uenced with the various
levels of the speci¢c metabolic enzymes, which are, in turn,
in£uenced by genetic polymorphisms and life-styles of individ-
uals. In contrast, gene targeted mice have a congenic back-
ground after completion of back crossing. They are consid-
ered to have equal levels of all other physiological and
biochemical enzyme activities except the gene targeted en-
zyme. Therefore, it is expected that the Aldh2 knockout mouse
generated in this study would be suitable to ascertain the
e¡ect of Aldh2 polymorphism on the chemical toxicity at
the level of the whole body.
It is likely that ALDH2*1/*2 and *2/*2 individuals are de-
fective in ME metabolic capacity at the whole body level, too.
ALDH2*1/*2 or *2/*2 carrying individuals are seen in Mon-
goloids and native Americans, and in about 50% of Japanese
[35]. Moreover, disul¢ram (Antabuse), an inhibitor of ALDH,
is used by many alcoholic patients, and some antibiotics also
decrease ALDH activity [36]. Individuals who are de¢cient in
ALDH2 activity may be especially susceptible to the e¡ects of
ME. The di¡erences of reproductive and hematological tox-
icity of ME due to ALDH2 polymorphism especially should
be clari¢ed at the in vivo level. Congenic Aldh2 targeted mice
would be an instrument in investigating the e¡ects of ALDH2
genetic polymorphism, including susceptibility to ME.
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